Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance

The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.

Biogen facility
Biogen investors are focused on the fate of aducanumab • Source: Alamy

More from Neurological

More from Therapy Areas